Reader Comments
Post a new comment on this article
Post Your Discussion Comment
Please follow our guidelines for comments and review our competing interests policy. Comments that do not conform to our guidelines will be promptly removed and the user account disabled. The following must be avoided:
- Remarks that could be interpreted as allegations of misconduct
- Unsupported assertions or statements
- Inflammatory or insulting language
Thank You!
Thank you for taking the time to flag this posting; we review flagged postings on a regular basis.
closeReferee comments: Referee 2 (P.P.Philippov)
Posted by PLOS_ONE_Group on 03 Mar 2008 at 13:18 GMT
Referee 2's review (P.P.Philippov):
This is very clear, interesting and professional work. The only problem, which I had after reading the article as a reviewer, was the absence of any critical notes. It would be of interest to know whether VILIP could play a similar role in another type of cancer such as SCLC.
**********
N.B. These are the comments made by the referee when reviewing an earlier version of this paper. Prior to publication the manuscript has been revised in light of these comments and to address other editorial requirements.
RE: Referee comments: Referee 2 (P.P.Philippov)
akleinszanto replied to PLOS_ONE_Group on 06 Mar 2008 at 20:42 GMT
Thanks very much for your comment. We have shown the VILIP-1 expression is absent in numerous tumor cell lines from sites other than lung (Figure 1). Furthermore, we have recently published that this protein is absent in aggressive squamous cell carcinomas of the esophagus (reference 5). This is mentioned now in the Discussion. The reason we did not include SCLC (apart from the fact that they constitute a small minority of lung tumors) is purely practical, i.e., since these tumors are usually not surgically excised, we did not have enough samples in our Tumor Bank to perform a study with sufficient power to correlate expression with clinical parameters.